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We examined the effect of chondroitin sulfate (CS), a compound used in the treatment of osteoarthritis
and joint pain, on the formalin-induced tactile allodynia in mice. A repeated oral administration of CS
(300 mg/kg, b.i.d.) signiﬁcantly ameliorated the formalin-induced tactile allodynia from day 10 after
formalin injection. On day 14, the phosphorylation of spinal p38 MAPK and subsequent increase in c-Fos-
immunoreactive dorsal lumbar neurons were attenuated by the repeated administration of CS. These
ﬁndings suggest that CS attenuates formalin-induced tactile allodynia through the inhibition of p38
MAPK phosphorylation and subsequent up-regulation of c-Fos expression in the dorsal lumbar spinal
cord.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Chondroitin sulfate (CS) is a glycosaminoglycan with poly-
saccharide chains composed of an alternate sequence of D-glucur-
onic acid and D-N-acetyl galactosamine linked by b(1 / 3) and
b(1 / 4) bonds, and is widely distributed in various connective
tissues such as cartilage, skin, corpus vitreum and blood vessels. CS
contributes to the viscoelastic property of the cartilage, and a
reduced level of CS in the cartilage has been reported to be a risk
factor for arthritic diseases in elderly people (1). CS is a compound
categorized as a symptomatic slow-acting drug for the treatment of
osteoarthritis (SYSADOA) because of its anti-inﬂammatory and
chondroprotective properties (2). CS is also popular in North
America as a dietary supplement intended to alleviate joint pain
(3). In Japan, CS is available as an over-the-counter drug used
against knee joint pain. Yet, the pain relief properties and mecha-
nism of CS remain unclear, though it has been suggested that CS
may play a role in pain relief through B2 bradykinin receptor
desensitization (4).
Thus, in the present study, we examined the effect of CS through
oral administration on the formalin-induced persistent tactile
allodynia in mice.No).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).Male ddY mice weighing 22e24 g were used throughout the
experiments. Mice were housed in cages with free access to food
and water under conditions of constant temperature (22 ± 2 C)
and humidity (55 ± 5%), on a 12 h lightedark cycle (lights on: 7:00
to 19:00). Group of 12 mice for behavioral experiments, 7 mice for
Western blotting, and 6e13 mice for immunohistochemical ex-
periments were used in single experiments. All experiments were
performed following the approval from the Ethics Committee of
Animal Experiment at Tohoku Medical and Pharmaceutical
University.
Formalin (Wako Pure Chemical Industries, Osaka, Japan) was
prepared as a 2% solution (0.74% formaldehyde in saline) then 20 ml
were injected in the right hindpaw under the skin of the plantar
surface using a 26-gauge microsyringe. CS (sodium chondroitin
sulfate from swine cartilage supplied from Zeria Pharmaceutical
Co., Tokyo, Japan) was dissolved in distilled water and orally
administered twice daily starting 24 h after the formalin injection.
Tactile allodynia was determined by assessing paw withdrawal
using the von Frey ﬁlament test. Mice were placed on a mesh ﬂoor
inside a clear plastic cubicle for an acclimatization period of a least
30 min before the test. After adaptation to the testing environ-
ment, the von Frey ﬁlament was pressed perpendicularly against
the plantar surface of the right hindpaw from beneath the mesh
ﬂoor and held for 3 s with the ﬁlament slightly buckled. A positive
response was noted if the paw was sharply withdrawn. Whenevernese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Effect of CS on formalin-induced tactile allodynia in mice. The threshold for paw withdrawal to von Frey ﬁlaments was monitored during 21 days after the injection of
formalin or saline. CS or water was orally administered twice daily starting 24 h after the formalin or saline injection. The threshold was measured before the ﬁrst daily
administration of CS or water. Values represent the means ± S.E.M. for groups of 12 mice. Two-way ANOVA: group (F4,55 ¼ 98.11, p < 0.01), time (F7,385 ¼ 73.40, p < 0.01),
group time (F28,385 ¼ 5.42, p < 0.01). One-way ANOVA: pre, F4,55 ¼ 0.68, p ¼ 0.61; 1 day, F4,55 ¼ 54.81, p < 0.01; 3 days, F4,55 ¼ 76.65, p < 0.01; 5 days, F4,55 ¼ 52.44, p < 0.01; 7 days,
F4,55 ¼ 23.86, p < 0.01; 10 days, F4,55 ¼ 33.79, p < 0.01; 14 days, F4,55 ¼ 23.75, p < 0.01; 21 days, F4,55 ¼ 10.91, p < 0.01. **p < 0.01 compared with the saline-water group and
##p < 0.01, #p < 0.05 compared with the formalin-water group.
Fig. 2. Change in phospho-p38 MAPK levels in the lumbar spinal cord induced by
formalin and the effect of CS treatment. CS (300 mg/kg) or water was orally admin-
istered twice daily starting 24 h after the formalin or saline injection, and spinal cord
samples were collected on day 14. Top: representative Western blot showing phospho-
and total-p38 MAPK. Bottom: relative quantiﬁcation of phospho-p38 MAPK to total-
p38 MAPK set as 1.0 in the saline/water group. Each value represents the
means ± S.E.M. of 7 mice in each group. Two-way ANOVA: group (F1,12 ¼ 12.23,
p < 0.01), treatment (F1,12 ¼ 6.75, p < 0.01), group  treatment (F1,12 ¼ 8.93, p < 0.05).
One-way ANOVA: F3,24 ¼ 8.94, p < 0.01. **p < 0.01 compared with the saline/water
group, ##p < 0.01 compared with the formalin/water group.
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Frey hair was applied whereas the pressure was increased one
level in the absence of a withdrawal response. Ambulation was
considered an ambiguous response, and in such cases the stimulus
was repeated.
Confocal microscopy observation and Western blotting were
carried out as previously described (5). For immunoﬂuorescence
double labeling, 40 mm-thick slices were incubated with mouse
anti-neuronal nuclei (NeuN) antibody (Millipore Co., MA, USA) and
rabbit anti-c-Fos antibody (Cell Signaling Technology, MA, USA)
overnight at 4 C. These primary antibodies were diluted 1:200 and
1:100, respectively, with PBS containing 0.3% Triton-X and 1%
normal goat serum (NGS; Invitrogen, CA, USA). Then, Alexa Fluor
488-conjugated goat anti-mouse IgG (Molecular Probes, OR, USA)
and Alexa Fluor 647-conjugated Fab fragment goat anti-Rabbit IgG
(Jackson ImmunoResearch Laboratories, PA, USA) (diluted 1:200
with PBS containing 0.3% Triton-X and 1% NGS) were allowed to
react in the dark at room temperature for 2 h. Fluorescence was
visualized on a D-Eclipse C1 microscope (Nikon, Tokyo, Japan). For
Western blotting, we used rabbit antibodies against p38 MAPK
(Cell Signaling Technology) or phospho-p38 MAPK (Cell Signaling
Technology), followed by HRP-conjugated anti-rabbit IgG antibody
(Cell Signaling Technology) as primary and secondary antibodies,
respectively. The density of the corresponding bands was analyzed
using Image-J 1.43u (National institute of Health).
Data are expressed as means ± SEM. Signiﬁcant differences
were analyzed by a one-way or two-way analysis of variance
(ANOVA), followed by Fisher's PLSD test for multiple-comparisons.
Student's t-test was used for comparisons between two groups. In
all comparisons, p < 0.05 was considered statistically signiﬁcant.
Clinical trials have reported a beneﬁcial effect of CS, either
alone (6) or in combination with glucosamine (7) on pain in pa-
tient with osteoarthritis. Although it is not a rapidly acting agent
such as nonsteroidal anti-inﬂammatory drugs (NSAIDs), as a
SYSADOA, CS contributes to reducing NSAIDs consumption in
osteoarthritis patients. In this study, the repeated administration
of CS (300 mg/kg, b.i.d.) signiﬁcantly prevented the decrease in the
ipsilateral paw withdrawal threshold from day 10 after formalin
injection (Fig. 1). Thus, it took 9 days for CS to exhibit its anti-
allodynia properties. One reason that may explain the delayed
action is the fact that CS is poorly absorbed through the gastro-
intestinal tract because of its high molecular weight (5e50 kDa)
and highly negative surface charge (8).
Fig. 3. Change in c-Fos expression in lumbar superﬁcial dorsal horn neurons induced by formalin and the effect of CS treatment. CS (300 mg/kg) or water was orally administered
twice daily starting 24 h after the formalin or saline injection, and spinal cord samples were collected on day 14. AeC: photomicrographs showing c-Fos-immunoreactive cells in the
ipsilateral dorsal spinal cord (L5) of saline/water (A), formalin/water (B) and formalin/CS (C) groups. DeF: double immunoﬂuorescence staining for c-Fos (magenta) and NeuN
(green) in the ipsilateral superﬁcial dorsal horn of saline/water (D), formalin/water (E) and formalin/CS (F) groups. Scale bar ¼ 100 mm. (G) Number of c-Fos/NeuN double positive
cells in the superﬁcial dorsal horn (laminae IeIII). Values represent the means ± S.E.M. for groups of 6e13 mice. One-way ANOVA: F2,27 ¼ 27.58, p < 0.01. **p < 0.01 compared with
the saline/water group, #p < 0.05 compared with the formalin/water group.
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phosphorylation is closely related to its anti-inﬂammatory effects.
In chondrocytes, the phosphorylation of p38 MAPK induced by
interleukin-1b (9) or lipopolysaccharide (10) was inhibited by CS.
On the other hand, in the spinal cord, p38 MAPK activation is
involved in formalin-induced tactile allodynia since the latter was
ameliorated by the intrathecal injection of the p38 MAPK inhibitor
SB203580 (11). In addition, while p38 MAPK is activated by the
upstream kinase MKK3/6, the initiation of formalin-induced tactile
allodynia was shown to be delayed in MKK3/ mice (12).
Therefore, to investigate whether p38 MAPK phosphorylation can
be attenuated by CS, we examined its effect on the phosphoryla-
tion of p38 MAPK in the dorsal spinal cord on day 14 after formalin
injection, a time-point that showed a marked anti-allodynic effect
of CS. As shown in Fig. 2, formalin induced the phosphorylation of
p38 MAPK in the dorsal lumbar spinal cord whereas this increase
was signiﬁcantly attenuated by the repeated administration of CS
(300 mg/kg, b.i.d. for 13 days). This result suggests that the anti-
allodynic effect of CS is due to the inhibition of formalin-induced
spinal p38 MAPK phosphorylation.
The immediate early gene protein product c-Fos has been
shown to be expressed in the dorsal horn neurons following a
nociceptive stimulus (13). The expression of c-Fos has beenwidely
accepted as an endogenous marker for neuronal reactivity and an
increase in expression in the superﬁcial dorsal horn was previ-
ously observed after the injection of formalin (14). On day 14, the
immunoﬂuorescence intensity for c-Fos increased in the superﬁ-
cial dorsal horn (laminae IeIII) of the formalin/water group but the
increase was attenuated in the CS-treated group (300 mg/kg, b.i.d.for 13 days) (Fig. 3AeC). The number of cells positive for NeuN (a
speciﬁc marker for mature neurons) that were also positive for
c-Fos increased approximately 5.5-fold in the formalin/water
group compared with the saline/water group, and the increase in
double-positive cells was partially but signiﬁcantly lessened by CS
treatment (Fig. 3DeG). Svensson et al. have reported that the
formalin-induced spinal c-Fos expression was attenuated by the
intrathecal administration of the p38 MAPK inhibitor SD-282 (14),
suggesting that an increase in c-Fos expression after the injection
of formalin is preceded by the activation of spinal p38 MAPK.
Although ERK1/2 was also phosphorylated in the dorsal spinal
cord of the formalin/water group, the increase in phospho-ERK1/2
was not affected by CS treatment (data not shown). Since spinal
ERK1/2 activation is also involved in c-Fos up-regulation (15), it
seems that CS only partially prevented the increase in the number
of c-Fos-immunoreactive neurons by formalin, despite the fact
that it almost completely attenuated the formalin-induced phos-
phorylation of p38 MAPK.
In conclusion, our data show that the repeated oral adminis-
tration of CS attenuates the formalin-induced persistent tactile
allodynia. The mechanism underlying the CS-induced anti-allody-
nia may be mediated through the inhibition of spinal p38 MAPK
activation and subsequent up-regulation of c-Fos expression in the
lumbar superﬁcial dorsal horn neurons.
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